Literature DB >> 12629236

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease.

T Foroud1, S K Uniacke, L Liu, N Pankratz, A Rudolph, C Halter, C Shults, K Marder, P M Conneally, W C Nichols.   

Abstract

BACKGROUND: The vast majority of the parkin mutations previously identified have been found in individuals with juvenile or early onset PD. Previous screening of later onset PD cohorts has not identified substantial numbers of parkin mutations.
METHODS: Families with at least two siblings with PD were ascertained to identify genes contributing to PD susceptibility. Screening of the parkin gene, by both quantitative PCR and exon sequencing, was performed in those families with either early onset PD (age onset < or =50 years) or positive lod score with a marker in intron 7 of the parkin gene.
RESULTS: A total of 25 different mutations in the parkin gene were identified in 103 individuals from 47 families. Mutations were found in both parkin alleles in 41 of the individuals, whereas a single mutation in only one of the two parkin alleles was observed in 62 individuals. Thirty-five of the subjects (34%) with a parkin mutation had an age at onset of 60 years or above with 30 of these 35 (86%) having a detectable mutation on only one parkin allele. Few significant clinical differences were observed among the individuals with two, one, or no mutated copies of the parkin gene.
CONCLUSION: Mutations in the parkin gene occur among individuals with PD with an older age at onset (> or =60 years) who have a positive family history of the disease. In addition, the clinical findings of parkin-positive individuals are remarkably similar to those without mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629236     DOI: 10.1212/01.wnl.0000049470.00180.07

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  68 in total

1.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

2.  Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.

Authors:  Hsin F Chien; Christan F Rohé; Maria D L Costa; Guido J Breedveld; Ben A Oostra; Egberto R Barbosa; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2005-11-22       Impact factor: 2.660

3.  A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.

Authors:  D M Kay; C F Stevens; T H Hamza; J S Montimurro; C P Zabetian; S A Factor; A Samii; A Griffith; J W Roberts; E S Molho; D S Higgins; S Gancher; L Moses; S Zareparsi; P Poorkaj; T Bird; J Nutt; G D Schellenberg; H Payami
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

4.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

5.  High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease.

Authors:  Christopher Schroeder; Michael Walter; Daniela Berg; Petra Leitner; Peter Bauer; Zacharias Kohl; Jürgen Winkler; Olaf Riess; Michael Bonin
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

Review 6.  Genetics of Parkinson disease.

Authors:  Nathan Pankratz; Tatiana Foroud
Journal:  NeuroRx       Date:  2004-04

Review 7.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

8.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

Review 9.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

10.  Genomewide association study for onset age in Parkinson disease.

Authors:  Jeanne C Latourelle; Nathan Pankratz; Alexandra Dumitriu; Jemma B Wilk; Stefano Goldwurm; Gianni Pezzoli; Claudio B Mariani; Anita L DeStefano; Cheryl Halter; James F Gusella; William C Nichols; Richard H Myers; Tatiana Foroud
Journal:  BMC Med Genet       Date:  2009-09-22       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.